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A major genomic region involved in Wegener’s granulomatosis includes the gene for retinoid receptor beta (RXRB) which forms
heterodimers with peroxisome proliferator-activated receptors (PPARs). It is unclear whether this association directly arises from
the RXRB allele(s) or via a linked variation. In order to reveal any hitherto unknown and potentially disease-relevant variation of
the RXRB gene, we have genotyped four tagging SNPs of this genomic region and have directly sequenced selected WG patients
and controls representing disease-associated haplotypes. Additionally, we have genotyped 2 SNPs each in the genes for PPARα and
PPARγ (PPARA and PPARG). Hence, we conﬁrmed the strong association of the RXRB locus with WG but could not reveal any
novel variation in RXRB.N o n eo ft h ePPARA and PPARG SNPs showed association with WG. Moreover, no epistatic eﬀect was
seen between RXRB and PPARA/PPARG alleles. These results do not support an etiopathological role of PPAR in WG. Analyses of
further genes functionally linked to RXRB may provide additional data useful to evaluate the RXRB association found in WG.
Copyright © 2009 Stefan Wieczorek et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Wegener’s granulomatosis (WG) is a form of small vessel
vasculitis belonging to the group antineutrophil cytoplasmic
antibody- (ANCA-) associated vasculitides (AAV). WG usu-
ally presents with granulomatous lesions of the upper res-
piratory tract and often develops into generalized vasculitis
with multiple organ involvement in later disease stages. In
WG ANCA typically recognize proteinase 3, delineating this
diagnostic entity from other AAV forms like Churg Strauss
syndrome or microscopic polyangiitis, in which ANCA are
usually directed against myeloperoxidase (reviewed in [1]).
Current concepts of its etiopathology are incomplete, but
WG is accounted to the large and heterogenous group of
complex disorders arise from a mostly elusive interplay of
environmental and genetic factors.
A major genomic locus for WG was identiﬁed on
chromosome 6p21.3, including (among others) the genes for
HLA-DPB1, RXRB,a n dRING1 [2]. The linkage disequilib-
rium (LD) pattern of this genomic region is complex with
larger blocks of strong LD alternating with regions of high
recombination rates. There is evidence that the association
of this locus with the disorder may arise from more than
one variation, making 6p21.3 a quantitative trait locus for
WG. While a strong association is demonstrable with the
HLA-DPB1∗0104 allele, a (partly) independent association
was detected for the deﬁned region including potential WG
candidate genes RING1 and RXRB [3]. In addition certain
alleles of RXRB, the gene encoding retinoid X receptor beta,
are highly signiﬁcantly associated with WG susceptibility [4].
Peroxisome proliferator-activated receptors (PPAR) are
group of nuclear receptors mediating the eﬀects of peroxi-
someproliferatorsongenetranscription.BindingofPPARto
regulatory DNA sequences requires the heterodimerization
with RXR. PPAR mediated eﬀects are complex and include
modulation of inﬂammatory processes. PPARα is a ligand
for leukotriene B4, and PPARα deﬁcient mice show a
prolonged response to inﬂammatory stimuli [5]. PPARα also
appears to be involved in downregulation of the activity
of cyclooxigenase 2 (COX2) and nuclear factor kappa-b
(NFκB). Likewise, PPARγ exhibits anti-inﬂammatory prop-
erties.Itisupregulatedinactivatedmacrophagesandinhibits2 PPAR Research
the expression, for example, of the inducible nitric oxide
synthase [6].
Genetic polymorphisms of PPAR have been investigated
in numerous conditions, predominantly in metabolic disor-
ders like type 2 diabetes or atherosclerosis [7–9]. There is
evidence for accelerated atherosclerosis in WG patients [10],
suggesting that both conditions may share some (genetic)
risk factors.
Given the pleiotropic role of PPAR in the regulation of
(vascular) inﬂammation, we have hypothesised that genetic
predisposition to WG may arise from the interaction of
certain genetic variations of RXRB and PPAR. We have,
therefore,screenedtheRXRBgenefornovel,potentiallyWG-
speciﬁc variations. Moreover, we have genotyped two single
nucleotide polymorphisms in each of the genes for PPARα
and PPARγ in large panels of WG cases and healthy controls.
Finally, we searched for epistatic eﬀects of certain alleles of
RXRB and PPARA or PPARG.
2. Patientsand Methods
2.1. Subjects. All patients included in this study were diag-
nosed with WG according to the criteria of the American
College of Rheumatology and the Chapel Hill consensus
conference [11]. They were selected at the interdisciplinary
vasculitis centre at the University of Luebeck/Rheumaklinik
Bad Bramstedt. All patients were asked for their ancestry and
reportedGermandecentforatleasttwogenerations.Healthy
Germanblooddonorswereusedascontrolsandancestrywas
evaluated equal to the patient group.
For the RXRB locus we genotyped the same patients (n =
282) and controls (n = 380) that were previously analyzed
forthe6p21.3locus[3].Inordertoincreasestatisticalpower,
the SNP in the PPAR genes were analyzed in expanded
sample comprising 462 WG cases and 701 controls.
Ethical principles for medical research involving human
subjects as deﬁned in the Declaration of Helsinki have been
followed. The study design was approved by the local ethics
committee at the University of Luebeck, Germany (No. AZ
06-087).
2.2. Genotyping. Four types SNPs rs9277935, rs2072915,
rs2744537, and rs1547387 (see Figure 1) were selected from
the HapMap database to serve as tagSNPs for a region
of 10kb including the RXRB gene. With this selection
all HapMap SNPs within this region are eﬃciently tagged
(r2 > 0.9). rs2072915 and rs2744537 are located within
the 3  untranslated region (UTR) of RXRB, while rs9277935
is located approximately 1kb 3  of the last RXRB exon.
rs1547387 is located 5  of RXRB, in exon 5 of the SLC39A7
gene, in which it constitutes a silent SNP (Ser209Ser).
rs9277935, rs2072915, and rs2744537 were genotyped
via PCR-RFLP techniques and a commercially available
TaqMan genotyping assay (Applied Biosystems) was used for
rs1547387.
For rs1800206 (Val162Leu) in PPARA also a commer-
cially available TaqMan assay was used, while rs6008259
(3  UTR of PPARA), rs1801282 (PPARG, Ala12Pro), and
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Figure 1: Location of the four tagging SNPs of the RXRB gene and
LD structure. The LD is plotted as D  and intensity coded (darker
shades corresponding to higher degree of LD). The RXRB gene is
transcribed from centromer to telomer, that is, from right to left.
RXRB exons are depicted as black boxes, and translation start and
stop points are marked by white vertical lines.
rs3856806 (PPARG, His449His) were genotyped using newly
designed primers and probes (see Table 1).
2.3.DirectSequencingofRXRB. TheentireRXRBgene(all10
exons and exon/intron boundaries) was directly sequenced
in 5 WG patients typed homozygous for the associated
RXRB haplotype (see below; primer sequences available on
request). For comparison 5 healthy controls homozygous for
the inversely associated (i.e., protective) haplotype were also
sequenced.
2.4. Statistical Analysis. Genotypes were recorded in linkage
format. Association for each single marker was tested by
using chi square tests on contingency tables. A P value
<.05 was considered signiﬁcant. LD between each SNP of
a respective locus, and haplotype block frequencies were
calculated by using Haploview 4.1 [12].
Interaction between RXRB and PPARA/PPARG SNPs
werecalculatedwithGAIA(http://gump.qimr.edu.au/GAIA/
gaia.html;[ 13]). This application uses a logistic regression
model which tests for pairwise locus/locus interactions
between genes. We applied an additive interaction model for
each pair of SNPs testing the signiﬁcance of the interaction
model terms over and above any main eﬀects.
3. Results and Discussion
The overall call rate for all 8 SNPs in patients and controls
was 93.60%. None of the SNPs revealed signiﬁcant devia-
tion from Hardy-Weinberg equilibrium. Two of the RXRB
SNPs (rs9277935 and rs2744537) showed highly signiﬁcant
association with WG (see Table 2). Accordingly, the GTTC
haplotype (calculated from all four SNPs of this locus)
was signiﬁcantly more common in WG while the TTGC
haplotype was overrepresented in controls (see Table 2).PPAR Research 3
Table 1: Oligonucleotides and restriction enzymes used for genotyping.
Gene SNP Forward (F) and reverse
(R) primer (5  > 3 ) Allele speciﬁc probes Restriction
enzyme Fragment lengths
RXRB
rs9277935 F: TGCCCCTTGTAG-
GTCTCCAC (1) — BtgI T-Allel: 208bp
T/G R: CCTCCCACTGTG-
CCCTAA G-Allel: 34+174bp
rs2072915 F: ACATCTCCACCA-
GCCCCTTC — MboI T-Allel: 325bp
T/A R: GTCCTTCCCCCA-
GCACAAAG A-Allel: 224+101bp
rs2744537 F: TCTTCAAGCTCA-
TTGGTGAC — BsaI T-Allel: 451bp
T/G R: CCCATTTCCACT-
CTTCAGAT G-Allel: 326+125bp
rs1547387
Information not
provided by the
manufacturer
——
C/G
PPARA
rs1800206
Information not
provided by the
manufacturer
——
G/C
rs6008259 F: CCCCTGTGTCAA-
CAAGATCCA
G: Fam-CTGTGTTGTCC-
CCAGCGACCC ——
G/A R: CTTGAATGGCAC-
AGGGTACATC
A: YY-CCTGTGTTGTCC-
CCAACGACCC
PPARG
rs1801282 F: TTATGGGTGAAA-
CTCTGGGAGATT
G: Fam-TCCTATTGACG-
CAGAAAGCGATTCC ——
G/C R: TTGTGATATGTT-
TGCAGACAGTGTATC
C: YY-TCCTATTGACCC-
AGAAAGCGATTCCTT
rs3856806 F: CCAGAAAATGAC-
AGACCTCAGACA
T: Fam-TCACGGAACAT-
GTGCAGCTACTGC ——
T/C R: GGAGCGGGTGAA-
GACTCATG
C: YY-ATTGTCACGGAA-
CACGTGCAGCTAC
(1) A 17mer nucleotide (GTAAAACGACGGCCAGT) was added 5  to the forward primer increase fragment length diﬀerences between the two alleles,
FAM: 6-carboxy-ﬂuorescein; YY: Yakima Yellow.
Based on the SNP data we have then selected 5 WG
patients homozygous for the GTTC haplotype for direct
sequencing of the RXRB gene. For comparison 5 control
subjects homozygous for the TTGC haplotype were also
analyzed. Yet, no novel sequence variation was detected,
a ﬁnding which is consistent with previous results from
Szyld et al. [4], who had screened the RXRB gene in WG
patients without consideration of the haplotype structure of
this locus. Results from the initial tagging SNP genotyping
were conﬁrmed in the ten included individuals for the two
exonic tagging SNPs (rs2744537 and rs2072915). Two other
exonic SNPs (rs1152296 in exon 10/5 UTR and rs6531 in
exon 7) were identiﬁed and perfectly segregated with the
previously identiﬁed risk/nonrisk haplotypes.
Both associated RXRB SNPs (rs9277935 and rs2744537)
are in strong LD with HLA-DPB1 as well as with rs3117228
and rs213208 (see Figure 2) which had revealed the highest
(and partly HLA-DPB1 independent) association with WG
in a previous study [3]. Moreover, according to the HapMap
data rs2744537 is in strong LD with rs6531 (a synonymous
S N Pi ne x o n7o fRXRB) which was signiﬁcantly associated
with WG earlier [4]. As for the other associated SNPs in this
genomic region, it is therefore hard to diﬀerentiate which of
the SNPs (or even a yet unknown variation of this locus)
constitutes the primary WG risk factor. A potential approach
to overcome this problem is the analysis of factors related
to the diﬀerent proteins encoded in the 6p21.3 region. We
have therefore investigated SNPs in the genes for PPARα and
PPARγ which are functionally closely linked to RXRB.
The two SNPs in PPARG were in weak to moderate
LD (D  = 0.64, r2 = 0.40) while the two SNPs in PPARA
were virtually unlinked (D  = 0.47, r2 = 0.06). Therefore, no
haplotype frequencies were calculated for these genes. Both
SNPs in PPARG showed very similar allele frequencies in
cases and controls not revealing any signiﬁcant diﬀerences
(see Table 2). The two SNPs in PPARA both revealed a4 PPAR Research
Table 2: Allele and haplotype frequencies.
Gene SNP/haplotype Allele Frequency in controls Frequency WG patients P value OR (95% CI)
RXRB
rs9277935
G 0.76 0.89 6.65 × 10−9 2.55 (1.86–3.56)
T 0.24 0.11
rs2072915
T 0.71 0.75 .157 1.20 (0.93–1.55)
A 0.29 0.25
rs2744537
T 0.73 0.57 6.63 × 10−9 0.49 (0.39–0.63)
G 0.27 0.43
rs1547387
C 0.87 0.85 .34 0.85 (0.62–1.18)
G 0.13 0.15
RXRB∗
GTTC 0.24 0.40 1.15 × 10−9 2.11 (1.66–2.69)
TTGC 0.19 0.07 9.73 × 10−10 0.32 (0.22–0.47)
other 0.43 0.47 .157 1.18 (0.94–1.47)
PPARA
rs1800206
C 0.93 0.95 .076 1.40 (0.96–2.05)
G 0.07 0.05
rs6008259
G 0.80 0.83 .069 0.81 (0.65–1.02)
A 0.20 0.17
PPARG
rs1801282
C 0.85 0.85 .74 0.96 (0.75–1.23)
G 0.15 0.15
rs3856806
C 0.86 0.85 .70 0.95 (0.75–1.22 )
T 0.14 0.15
OR: Odds ratio,
CI: conﬁdence interval,
∗haplotype frequencies calculated from all four RXRB SNPs.
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Figure 2: LD between WG associated variations of the 6p21.3
genomic region. HLA-DPB1 is modelled as a biallelic marker with
the associated HLA-DPB1∗0401 as one allele and all other alleles
joint into the other allelic category. LD is plotted as D  and intensity
coded (darker shades corresponding to higher degree of LD). Both
RXRB SNPs investigated in this study (rs9277935 and rs2744537)
are in high LD with HLA-DPB1 as well as with the markers analyzed
by Heckmann et al. (2008): rs3117228 (3  of HLA-DPB1)a n d
rs213208 (intronic SNP in RING1,a p p r o x .1 0 k bc e n t r o m e r i co f
RXRB).
decreased frequency of the minor allele but these diﬀerences
did not reach signiﬁcance level (see Table 2). No signiﬁcant
pairwise epistatic eﬀect for any of the investigated SNPs,
that is, neither between PPARA and PPARG nor between
PPARA (or PPARG,r e s p . )a n dRXRB or HLA-DPB1.T a k e n
together, we cannot provide evidence for a genetically based
involvement of PPARα and PPARγ in the etiopathology of
WG. Moreover, the strong WG association with the 6p21.3
locus is unlikely to be based on any coding variation of the
RXRB gene. Future studies will therefore have to focus on
regulatory elements of this area (e.g., cis acting elements or
micro RNAs).
4. Conclusions
These results do not support a direct etiopathological role
of RXRB and/or PPAR in WG. Analyses of further genes
functionally linked to RXRB, for example, retinoic acid
receptors or vitamin D receptors, may provide additional
data useful to evaluate the RXRB association found in WG.
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